Still, its strong debut doesn’t erase uncertainty around the drug, which just stumbled in the clinic, as BMS looks to answer high-stakes questions about its long-term market potential.

In a statement, BMS said there were signs of improved performance with Cobenfy for certain patients, including a group treated with risperidone as the baseline antipsychotic versus those treated ...

BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 trial starts The cuts aren’t the first for BMS’ Lawrenceville team this year. Back in March ...

Bristol-Myers Squibb Company or BMS (BMY) released its first quarter ... The company's schizophrenia treatment, Cobenfy's failure to meet the primary endpoint in its recent trial is a ...

Yes. So, as you know, COBENFY was approved last year by the U.S. FDA for the treatment of schizophrenia in adults. And so BMS, who acquired Karuna has launched this product in the U.S., I believe ...

Bristol-Myers Squibb's new drug Cobenfy is showing strong prescription growth, hinting at possible earnings overperformance ...

Positive top-line results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of Cobenfy (xanomeline and trospium chloride) in ...

BMS did, however, report a win for the quarter, with sales of its growth portfolio—which includes Opdivo and Cobenfy—increasing 16% year over year to $5.6 billion.